Kingdon Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Kingdon Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-28,426	Closed	-$156K	–	108
2018 Q1	$156K	Hold	28,426	–	–	0.01%	104
2017 Q4	$226K	Sell	28,426 -14,286	-33%	-$128K	0.01%	109
2017 Q3	$302K	Sell	42,712 -280	-0.7%	-$2.11K	0.02%	116
2017 Q2	$337K	Sell	42,992 -7,211	-14%	-$58K	0.02%	96
2017 Q1	$401K	Sell	50,203 -42,654	-46%	-$395K	0.02%	104
2016 Q4	$1.36M	Buy	92,857 +36,171	+64%	+$541K	0.07%	113
2016 Q3	$980K	Buy	+56,686	New	+$1.83M	0.04%	113

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Kingdon Capital Management's ARCT Position: Q2 2018 in Review

Kingdon Capital Management sold out of Arcturus Therapeutics (ARCT) in Q2 2018, closing a stake of 28,426 shares — an estimated $156K sold.

Kingdon Capital Management first reported a position in ARCT in Q3 2016 and held it in 7 quarters. The position peaked at $1.36M in Q4 2016. 18 funds tracked by Wall St. Rank hold ARCT as of Q2 2018.

Kingdon Capital Management reported no remaining Arcturus Therapeutics position as of Q2 2018 after selling out during the quarter.
Kingdon Capital Management sold 28,426 Arcturus Therapeutics shares in Q2 2018, an estimated $156K.
Kingdon Capital Management first reported a position in Arcturus Therapeutics in Q3 2016 and held it in 7 quarters.
Kingdon Capital Management's Arcturus Therapeutics position peaked at $1.36M in Q4 2016.
18 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2018.

Based on Kingdon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.